Cash Flow Statement

Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Amortization - Goodwill EBIAT Leases Machine, Furnitures, Fixtures & Other Non-Current Receivables Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

Ratios

Sangamo Therapeutics (SGMO) Shares Issued (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Shares Issued for 16 consecutive years, with $52.0 million as the latest value for Q4 2025.

For Q4 2025, Shares Issued rose 17832.76% year-over-year to $52.0 million; the TTM value through Dec 2025 reached $52.2 million, up 17894.83%, while the annual FY2025 figure was $52.2 million, 17894.83% up from the prior year.
Shares Issued hit $52.0 million in Q4 2025 for Sangamo Therapeutics, up from -$21.4 million in the prior quarter.
Across five years, Shares Issued topped out at $52.0 million in Q4 2025 and bottomed at -$21.4 million in Q3 2025.
Average Shares Issued over 5 years is $3.9 million, with a median of $880000.0 recorded in 2021.
Year-over-year, Shares Issued tumbled 52550.0% in 2023 and then surged 17832.76% in 2025.
Sangamo Therapeutics' Shares Issued stood at $1.1 million in 2021, then crashed by 96.81% to $34000.0 in 2022, then tumbled by 2214.71% to -$719000.0 in 2023, then soared by 140.33% to $290000.0 in 2024, then soared by 17832.76% to $52.0 million in 2025.
According to Business Quant data, Shares Issued over the past three periods came in at $52.0 million, -$21.4 million, and $11.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.